Insider Trading & Ownership of Wei Lin

Location
San Diego, CA
Summary
The estimated net worth of Wei Lin is at least $10,680,626 dollars as of 19 Mar 2026. Wei Lin is the Chief Medical Officer of Revolution Medicines, Inc. and owns shares of Revolution Medicines, Inc. (RVMD) stock worth about $10.08M. Wei Lin is the Chief Medical Officer of Erasca, Inc. and owns shares of Erasca, Inc. (ERAS) stock worth about $502K. Wei Lin is the Director of 2seventy bio, Inc. and owns shares of 2seventy bio, Inc. stock worth about $94.7K.
Signature
/s/ Jack Anders, as Attorney-in-fact for Wei Lin
All Insider Reports
All Insider Reports

Follow Filing Activity

Follow Wei Lin and return when a new Insider Trading filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Create free account and return here Already have an account? Sign in and return here

Quick Takeaways

  • Wei Lin has 3 issuer positions tracked on this page.
  • Estimated disclosed ownership value: $10,680,626.
  • Recent insider filing activity is available below.

What Changed

  • Largest disclosed position: Revolution Medicines, Inc. ($10,083,930).
  • Past-year value change for that position: -$391,755.

Why This Matters

  • This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
  • You can cross-check role, issuer, and filing chronology directly against the SEC source.

Source Evidence

Filed on Form 4

Insider ownership context is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Ownership of Wei Lin

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
RVMD, RVMDW Revolution Medicines, Inc. Chief Medical Officer $10,083,930 -$391,755 -3.7% 17 Mar 2026
ERAS Erasca, Inc. Chief Medical Officer $501,983 01 Feb 2023
TSVT 2seventy bio, Inc. Director $94,713 13 May 2025

Insider Transactions Reported by Wei Lin:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .